Recent advances in molecular targeted therapy for metastatic renal cell carcinoma
نویسندگان
چکیده
منابع مشابه
VEGF-targeted therapy in metastatic renal cell carcinoma.
PURPOSE To review the biology of renal cell carcinoma (RCC) and the clinical results of vascular endothelial growth factor (VEGF) blockade in metastatic RCC. METHODS A review of relevant published literature regarding VEGF, von Hippel-Lindau (VHL) gene inactivation, and VEGF overexpression in RCC was performed. Further, a review of the mechanism, toxicity, and clinical development of VEGF-tar...
متن کاملRecent advances in molecularly targeted therapy in advanced renal cell carcinoma
Historical perspective Renal cell carcinoma (RCC) comprises approximately 2–3% of all malignancies in the USA with an estimated incidence of 39,000 cases and 13,000 deaths in 2008 [1]. RCC is comprised of several different histologic subtypes, with clear cell being the most common, comprising approximately 80% of all RCC. Papillary, chromophobe, oncocytic, collecting-duct, medullary and unclass...
متن کاملTargeted Therapy for Metastatic Renal Carcinoma: an Update
Conventional chemotherapy is associated with poor outcomes in metastatic renal cell carcinoma (RCC). Advances in the understanding of tumor molecular biology and the implementation of new drugs that target these molecular pathways have increased the arsenal against advanced RCC and improved outcomes in these patients. Herein, we briefly describe the latest data on targeted therapies used in the...
متن کاملSequential Therapy in Metastatic Renal Cell Carcinoma
The treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in the past decade. As the number of available agents, and related volume of research, has grown, it is increasingly complex to know how to optimally treat patients. The authors are practicing medical oncologists at the US Oncology Network, the largest community-based network of oncology providers in the country, a...
متن کاملRecent Advances in Hemophilia Gene Therapy
Heterogeneous loss of function mutations at F8 and F9 genes causes X-linked recessive bleeding disorders, hemophilia A (HA) and hemophilia B (HB), respectively. HA is clinically indistinguishable from HB and accounts for more than 80% of hemophilia cases; the former affects 1/5000 and the latter 1/25000 male births worldwide. In Iran, it is estimated that around 4300 HA and 900 HB patients are ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Urology
سال: 2009
ISSN: 0919-8172
DOI: 10.1111/j.1442-2042.2009.02277.x